Nalcrom Survey Report
In February and March 2021, MSC conducted a survey on access to the medication Nalcrom. This survey was in part in response to concerns raised by patients over appearance changes and efficacy changes in recent batches of Nalcrom. Following the completion of the survey, we have created a report that summarises the data collected and our efforts to advocate on behalf of our patient population.
In addition to publicly sharing this report on our website, we have shared it with Sanofi Canada and Health Canada.